Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Infection with hepatitis C genotype 1 or mixed hepatitis C genotype;
•Asymptomatic or nearly asymptomatic from hepatitis C;
•Previous therapy with interferon and ribavirin or peginterferon and ribavirin without an SVR or relapsed following an SVR;or Interferon naive subjects
•Chronically infected (at least 6 months since diagnosis) HCV-positive subjects;
•No evidence of bridging necrosis or cirrhosis;
•Liver biopsy within the last 2 years

•Acute hepatitis C infection
•History of prior malignancy, acquired or inherited immunodeficiency or autoimmune disease either documented or anecdotal;